Sat. Article : VRTX Now Has Market Valuation Comparanble tp REGN. posted.
Seeking Alpha 4/20/13 By Rod Raynbovich
Vertex has been a major player in the development of small molecule drugs to treat HCV and cystic fibrosis. Forecasts for the cystic fibrosis drug are in the $5B range and analysts have already jumped on the bandwagon proclaiming this mid-cap is ready to move into the majors as it now has a market valuation comparable to Regeneron (REGN) which has forecasted revenues of $1.9B.